OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology. The clinical study, OX640-002, evaluated both pharmacokinetic and pharmacodynamic effects of OX640 in subjects...
Hence then, the article about orexo announces positive topline data from clinical study of ox640 in subjects with and without allergic rhinitis was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis )
Also on site :
- Trump endorses Steven Hilton in California governor's race
- IAEA: Continued military activity near Bushehr Plant could cause radiological accident
- Pakistan offers two-stage truce plan to end US-Israel war: Report